MedTrace Logo

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-15

No results posted yet for this study

Summary

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Conditions

Interventions

DRUG

T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.

T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion

Sponsors & Collaborators

  • Blokhin's Russian Cancer Research Center

    lead OTHER

Principal Investigators

  • Elena Artamonova · The Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07281001 on ClinicalTrials.gov